Real-time polymerase chain reaction (PCR)-based detection and quantification of hepatitis B virus (HBV) DNA is a sensitive and accurate method for diagnosing and monitoring HBV infection. Here, we present a protocol for HBV DNA detection and the viral load measurement of a sample.
Hepatitis B virus (HBV) is a significant cause of liver disease worldwide. It can lead to acute or chronic infections, making individuals highly susceptible to fatal cirrhosis and liver cancer. Accurate detection and quantification of HBV DNA in the blood are essential for diagnosing and monitoring HBV infection. The most common method for detecting HBV DNA is real-time PCR, which can be used to detect the virus and assess the viral load to monitor the response to antiviral therapy. Here, we describe a detailed protocol for the detection and quantification of HBV DNA in human serum or plasma using an IVD-marked real-time PCR-based kit. The kit uses primers and probes that target the highly conserved core region of the HBV genome and can accurately quantify all HBV genotypes (A, B, C, D, E, F, G, H, I, and J). The kit also includes an endogenous internal control to monitor possible PCR inhibition. This assay runs for 40 cycles, and its cutoff is 38 Ct. For the quantification of HBV DNA in clinical samples, a set of 5 quantification standards is provided with the kit. The standards contain known concentrations of HBV-specific DNA that are calibrated against the 4th WHO International Standard for HBV DNA for the nucleic acid test (NIBSC code 10/266). The standards are used to validate the functionality of the HBV-specific DNA amplification and to generate a standard curve, allowing the quantification of HBV DNA in a sample. HBV DNA as low as 2.5 IU/mL was detected using the PCR kit. The high sensitivity and reproducibility of the kit make it a powerful tool in clinical laboratories, aiding healthcare professionals in effectively diagnosing and managing HBV infections.
Hepatitis B virus (HBV) is a partially double-stranded DNA virus from the genus Orthohepadnavirus and the Hepadnaviridae family1. It can trigger a chronic infection that persists throughout one's life, potentially leading to liver cirrhosis and hepatocellular carcinoma2,3,4. According to the World Health Organization (WHO), an estimated population of 296 million people were living with chronic hepatitis B infection in 2019, and 1.5 million people were newly infected each year5.
The identification and measurement of HBV DNA in serum or plasma samples serve as a valuable method for detecting individuals with an ongoing hepatitis B infection, assessing the efficacy of antiviral treatment, and predicting the probability of treatment success6,7,8,9,10,11. High viral load is associated with an increased risk of liver disease progression, including cirrhosis and liver cancer12,13. Hence, precise measurement of viral load is crucial for tracking the progression of HBV infection and informing decisions regarding treatment.
Quantitative real-time PCR assays have higher sensitivity, broader dynamic range, and more accurate quantification of HBV DNA than conventional PCR techniques14,15,16,17. Several commercial real-time PCR-based molecular diagnostic kits for the quantitation of HBV DNA in serum or plasma samples are available in the market. Here, we describe a detailed workflow for the detection and quantification of HBV DNA in human serum or plasma using a commercially available, IVD-marked real-time PCR-based kit. The kit is a widely used18,19, low-cost, yet highly sensitive assay, and its performance characteristics are comparable with other commercially available CE-marked kit(s)18. Apart from the HBV target region amplification, an endogenous internal control gene is also included in the kit to verify the quality of samples, quality of extracted DNA, PCR amplification, and possible PCR inhibition.
This study did not involve any human participants or clinical samples. The only biological material used was the 4th WHO International Standard for HBV DNA for nucleic acid test (NIBSC code 10/266). This standard is a publicly available reference material that does not contain any personal information or identifiable data. As such, no ethical approval was required for this study.
1. DNA Extraction
2. Real-time PCR
A schematic diagram of the workflow to detect and quantify HBV DNA from human plasma/serum is shown in Figure 1. An amplification plot of Standard 2 (used as a PC) and NTC for both HBV and IC is shown in Figure 2. Figure 3 shows the amplification curves for an HBV-positive sample, an HBV-negative sample, and a sample with PCR inhibition. The amplification curve, Ct value for HBV, and obtained HBV concentration in international units per microliter (IU/µL) for the NIBSC code 10/266 are shown in Figure 4. Amplification curves for the HBV target of all the 5 HBV standards of the kit and a representative standard curve for the same are shown in Figure 5. The slope of the standard curve is -3.361, R2 is 0.99996, and efficiency is 0.98. Amplification curves for the IC target of all 5 HBV standards are shown in Figure 6.
Figure 1: Schematic diagram of the workflow to detect and quantify HBV DNA from human plasma/serum samples. Extract viral DNA from human serum/plasma sample of HBV suspected individual. Prepare the PCR mix by adding each PCR component except the template DNA/ standard(s). Dispense it into PCR tubes/wells. Add the extracted viral DNA/ standard(s) as the template DNA, and close the PCR tubes. Load it into a real-time PCR machine, start the PCR run, and analyze the result after run completion. Please click here to view a larger version of this figure.
Figure 2: Amplification plot of Standard 2 (used as a PC) and NTC. An amplification plot of HBV standard 2 is shown here for both the HBV and IC targets. For qualitative result analysis, Standard 2 can be used as a positive control. For NTC, no amplification was observed for either of the targets. Please click here to view a larger version of this figure.
Figure 3: Amplification plots for HBV positive sample, HBV negative sample, and a sample with PCR inhibition. Amplification plots for three different samples: HBV positive (Case 1), HBV negative (Case 2), and a sample containing PCR inhibitors (Case 3) are shown here. In the case of the HBV positive sample, both the targets are amplified, whereas only IC was amplified for the HBV negative sample, and no amplification for the HBV target was observed as expected. Neither HBV nor IC was amplified for Case 3, which means PCR inhibition occurred due to the PCR inhibitors present in the DNA sample used as the PCR template. Please click here to view a larger version of this figure.
Figure 4: Amplification curve, Ct value for HBV, and obtained HBV concentration (IU/µL) for the NIBSC code 10/266. Extracted viral DNA of NIBSC code 10/266 was run along with the 5 HBV standards and NTC. The amplification curve for the HBV target is shown for the NIBSC code 10/266 sample in the upper panel. Its Ct value for HBV is 18.94, and the calculated concentration is 6659 IU/µL, shown in the lower panel. Please click here to view a larger version of this figure.
Figure 5: Amplification curves for the HBV target of all 5 HBV standards and the standard curve. Amplification curves for the HBV target (green channel) of all 5 HBV standards are shown in the upper panel. A standard curve along with its slope (3.361), R2 value (0.99996), and PCR efficiency (0.98) are shown in the lower panel. Please click here to view a larger version of this figure.
Figure 6: Amplification curves for the IC target of all 5 HBV standards. Amplification curves of 5 HBV standards for the IC (yellow channel) are shown here. As expected, they look the same with similar Ct values. Please click here to view a larger version of this figure.
Figure 7: Amplification curves for the HBV target of all 5 HBV standards and NTC were run in triplicate. The amplification plots of three replicates for the HBV target (Green channel) of the 5 HBV standards show similar results. Please click here to view a larger version of this figure.
Figure 8: Amplification curves for the HBV target of NIBSC code 10/266, NIBSC code 14/198, and its five dilutions. The amplification curves for the HBV target (green channel) of the reference samples NIBSC code 10/266, NIBSC code 14/198, and its five dilutions (1.25 IU/mL, 2.5 IU/mL, 5 IU/mL, 25 IU/mL, and 50 IU/mL) are shown here. No amplification was detected for 1.25 IU/mL, while other dilutions showed proper amplification curves before 38 Ct. Please click here to view a larger version of this figure.
Reagent | Description |
Multiplex master mix | PCR buffer, Hot Start Taq DNA polymerase, and other PCR components |
HBV primer probe mix | Primers and probe mix for HBV detection |
Endogenous IC primer probe mix | Primers and probe mix for endogenous internal control (IC) detection |
Standards for HBV | · HBV Standard 1 |
· HBV Standard 2 | |
· HBV Standard 3 | |
· HBV Standard 4 | |
· HBV Standard 5 | |
Negative Control | PCR grade nuclease-free water |
Table 1: Reagents supplied with the real-time PCR kit and their description
Reagent | Volume per reaction |
Multiplex master mix | 11 µL |
HBV primer probe mix | 2 µL |
Endogenous IC primer probe mix | 2 µL |
Total reaction volume | 15 µL |
Table 2: Volume of each reagent to be added per reaction for PCR mix preparation
Step | Temperature (°С) | Time | Data collection | Cycles |
Initial Denaturation | 94 | 10 min | – | 1 |
PCR cycling | 94 | 15 s | – | 40 |
55 | 60 s | On | ||
72 | 15 s | – |
Table 3: PCR cycling conditions
Target | Rotor-Gene Q* | CFX 96 | ABI real-time PCR# |
HBV | Green | FAM | FAM |
IC | Yellow | HEX | VIC |
*Auto-Gain Optimisation Setup- select 'Perform Optimisation Before 1st Acquisition’ | |||
#Only for Applied Biosystems’ real-time PCR machines, select ROX as the ‘Passive Reference’ dye during plate setup, as the master mix of the kit contains ROX |
Table 4: Dye selection for different real-time PCR platforms
Real Time PCR Instrument | Dyes | Threshold value range§ |
ABI real-time PCR¶ | FAM | 0.2–0.25 |
VIC | 0.05–0.12 | |
Bio-Rad CFX-96† | FAM | 100–800 |
HEX | 50–400 | |
Rotor-Gene Q | Green | 0.015–0.03 |
Yellow | 0.01–0.02 | |
§An absolute threshold value varies from instrument to instrument depending upon instrument’s age, model and calibration status | ||
¶These threshold values are applicable when ROX is selected as the ‘Passive Reference’ dye | ||
†Relative fluorescence is increased by about 2 to 5-fold when Bio-Rad's white PCR tubes are used instead of clear tubes. So, the threshold value should be determined accordingly |
Table 5: Recommended threshold values for different real-time PCR platforms
Sample type | Case | Amplification Signal in | Result Interpretation | |||
FAM/Green | HEX/VIC/Yellow | |||||
Control | Standard 2/PC | Yes (20 ± 2) | Yes (24 ± 3) | Standard 2/PC is working properly | ||
NTC | No | No | NTC is working properly | |||
Sample | 1 | Yes | Yes / No* | HBV specific DNA detected | ||
2 | No | Yes | HBV specific DNA not detected. Sample does not contain detectable amount of HBV specific DNA | |||
3 | No | No | Possible inhibition of PCR, dilute the DNA sample (1:10) / re-extract DNA from the original sample and repeat the PCR | |||
*Detection of the Internal Control is not required when the HBV target is detected. High HBV DNA load in the sample can lead to reduction or absence of Internal Control signal |
Table 6: Result interpretation of positive, negative, and PCR inhibitors containing poor-quality samples
Standard | Concentration (IU/µl) | Desired Ct | |
HBV | IC | ||
(FAM/ Green) | (HEX/VIC/Yellow) | ||
HBV Standard 1 | 5 X 104 | 17 ± 2 | 24 ± 3 |
HBV Standard 2 | 5 X 103 | 20 ± 2 | 24 ± 3 |
HBV Standard 3 | 5 X 102 | 23 ± 2 | 24 ± 3 |
HBV Standard 4 | 5 X 101 | 27 ± 2 | 24 ± 3 |
HBV Standard 5 | 5 X 100 | 31 ± 2 | 24 ± 3 |
Table 7: HBV standards and its concentration of the HBV target and desired Ct values
Sample | Expected Ct | Obtained Ct for HBV | Average Ct | Standard Deviation | CV % | ||
Replicate 1 | Replicate 2 | Replicate 3 | |||||
HBV Standard 1 | 17 ± 2 | 17.01 | 16.89 | 17.07 | 16.99 | 0.09 | 0.54 |
HBV Standard 2 | 20 ± 2 | 20.29 | 20.32 | 20.34 | 20.32 | 0.03 | 0.12 |
HBV Standard 3 | 23 ± 2 | 23.61 | 23.88 | 23.73 | 23.74 | 0.14 | 0.57 |
HBV Standard 4 | 27 ± 2 | 26.95 | 27.03 | 27.12 | 27.03 | 0.09 | 0.31 |
HBV Standard 5 | 31 ± 2 | 30.58 | 30.91 | 31 | 30.83 | 0.22 | 0.72 |
Table 8: Obtained Ct values, average, standard deviation, and coefficient of variation (CV%) of 5 HBV Standards.
NIBSC code 10/266 has been assigned a unit of 9,55,000 IU/mL when reconstituted in 0.5 mL of nuclease-free water as per the supplier information21. This can be considered a high-load HBV positive sample. The HBV viral load determined by the viral load kit used in this study was 6,65,900 IU/mL (Figure 4). As the DNA extraction efficiency of any DNA extraction kit is not 100%, some DNA is often lost during the purification process. Although the viral load determined by the kit is slightly lower than the reagent (NIBSC code 10/266) supplier's assigned value, still the data is satisfactory as the log10 difference between the two values is only 0.157 which is less than the cutoff value (0.5)22.
The viral load kit used in this protocol is highly robust and gives reproducible data, as shown in Figure 7. In this experiment, all 5 standards and NTC were run in triplicate, and their Ct values, average, standard deviation, and coefficient of variation (CV%) are shown in Table 8. A lower CV% of less than 1%, as mentioned in Table 8, indicates that the experiment is more reliable and produces highly accurate results.
A very low load reference sample (NIBSC code: 14/198)23 was used with the kit to check its LoD. NIBSC code 14/198 contains less than 50 IU/mL of HBV DNA per the supplier information. DNA was extracted from NIBSC code 14/198, and multiple dilutions (1.25 IU/mL, 2.5 IU/mL, 5 IU/mL, and 25 IU/mL) of the DNA were prepared. The kit used all the dilutions and 5 HBV standards as template DNA. It was observed that that kit can detect all dilutions up to 2.5 IU/mL of HBV DNA (Figure 8), and it exactly matches the LoD of the viral load kit. Hence, the viral load kit is a highly sensitive and reproducible tool that molecular diagnostic laboratories can use to aid healthcare professionals in diagnosing and managing HBV infections effectively.
Users should keep in mind the following critical steps when they perform the procedure. The users must employ only high-quality extracted DNA as the PCR template to ensure accurate results. It is important to avoid multiple freeze-thaw cycles (not more than 3 times) of the reagents. The PCR mix should not be exposed to light for a long time as it contains the light-sensitive fluorescent probe and passive reference dye ROX. It is critical to always include no template control and standards in each run to ensure the accuracy and reliability of the results. Calibrated pipettes with sterile filtered tips must be used always. The template DNA and standards must be added in a separate area with a different pipette from the reaction preparation area to avoid cross-contamination.
The following are some common troubleshooting tips for real-time PCR-based detection and quantitation of hepatitis B virus DNA. Amplification signal in negative control may happen due to cross-contamination during reaction setup. So, the user should check for contamination of kit components. No amplification signal with standards may occur due to the following reasons: (i) Incorrect PCR mixture used. The user should check whether all components are added correctly or not. (ii) Use of expired reagents. The user must check the expiry date before the reaction is set up. (iii) Improper storage of reagents. Ensure that the reagents are stored at -20 °C or below and not kept at room temperature for a long time during reaction setup. (iv) Wrong PCR cycling condition was used. In such a case, it is recommended to repeat the PCR with the correct program. (iv) Weak or no signal of the internal control for samples may occur due to high HBV load in the sample and PCR inhibition. The user could dilute the DNA sample (1:10) and repeat the assay for high HBV load in the sample. In the case of PCR inhibition, the sample DNA must be re-extracted with good-quality reagents, and the assay must be repeated.
Real-time PCR-based detection and quantitation of hepatitis B virus DNA is a very sensitive and specific technique, but it does have some limitations like cost and complexity. Real-time PCR instruments and reagents can be expensive, and the cost of testing can be a barrier for some patients and healthcare systems. Real-time PCR is a complex technique requiring trained personnel to perform the assay and interpret the results. It is an indirect measurement of the viral load, so both the quality of the standards and template DNA may influence the result. Novel genotype of the HBV and/or mutation(s) in the primer-probe region may lead to false negative results.
Real-time PCR-based detection and quantification of HBV DNA is a highly sensitive and specific method that can detect low levels of viral DNA. In comparison to other methods like serological tests (ELISA and lateral flow assay), real-time PCR has several advantages. Firstly, it is more sensitive than the serological tests. Secondly, it can quantify the amount of HBV DNA present in a sample, whereas serological tests can only provide a qualitative result. Finally, real-time PCR is less prone to false positives than the serological tests24. Overall, real-time PCR is the most sensitive, specific, and quantitative method available for the detection and quantitation of HBV DNA. It is also a relatively fast technique, which makes it ideal for clinical use.
Real-time PCR-based detection and quantitation of hepatitis B virus DNA is a powerful tool with several future applications, including developing new antiviral therapies and point-of-care testing. The technique can be used to screen new antiviral drugs and to monitor the efficacy of these drugs in clinical trials. This could lead to the development of more effective and less toxic treatments for HBV infection. Real-time PCR instruments are becoming smaller and more portable, making it possible to perform HBV viral load testing at the point of care. This could improve access to testing and lead to earlier diagnosis and treatment of HBV infection. The regents of this real-time PCR-based kit can be adapted with digital PCR for absolute quantification for more accurate monitoring of the vial load.
In addition to these specific applications, real-time PCR-based detection and quantitation of HBV DNA is likely to play an important role in the research and development of new tools and strategies for preventing, diagnosing, and treating HBV infection.
The authors have nothing to disclose.
We acknowledge Praveen, Kusum, Chandan, Isha, Rashmi, Babli, Shivani, Ankita, and Shikha for their technical assistance.
4th WHO International Standard for hepatitis B virus DNA | NIBSC | NIBSC code: 10/266 | The 4th WHO International Standard for hepatitis B virus (HBV) DNA, NIBSC code 10/266, is intended to be used for the calibration of secondary reference reagents used in HBV nucleic acid amplification techniques (NAT). |
ABI real-time PCR machines | ThermoFisher Scientific | ABI 7500; QuantStudio 5 | This is a real time PCR machine |
HBV, HCV and HIV Multiplex 14/198 | NIBSC | NIBSC code: 14/198 | This is a very low positive triplex reagent for NAT assays containing hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus-1 (HIV-1) |
QIAGEN real-time PCR machine | Qiagen | Rotor-Gene Q | This is a real time PCR machine |
TRUPCR HBV Viral Load kit | Kilpest India Limited | 3B294 | This is a real time PCR based kit used in this study for the HBV DNA detection and viral load determination |
TRUPCR Viral Nucleic Acid Extraction Kit | Kilpest India Limited | 3B214 | This is a DNA extraction kit used for the extraction of HBV viral DNA from NIBSC:10/266 and NIBSC:14/198 |